Product Details for NDA 216951
JESDUVROQ (DAPRODUSTAT)
1MG
Marketing Status: Discontinued
2MG
Marketing Status: Discontinued
4MG
Marketing Status: Discontinued
6MG
Marketing Status: Discontinued
8MG
Marketing Status: Discontinued
1MG
Marketing Status: Discontinued
Active Ingredient: DAPRODUSTAT
Proprietary Name: JESDUVROQ
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 1MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N216951
Product Number: 001
Approval Date: Feb 1, 2023
Applicant Holder Full Name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD ENGLAND
Marketing Status: Discontinued
Patent and Exclusivity Information
JESDUVROQ (DAPRODUSTAT)
Proprietary Name: JESDUVROQ
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 1MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N216951
Product Number: 001
Approval Date: Feb 1, 2023
Applicant Holder Full Name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD ENGLAND
Marketing Status: Discontinued
Patent and Exclusivity Information
2MG
Marketing Status: Discontinued
Active Ingredient: DAPRODUSTAT
Proprietary Name: JESDUVROQ
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 2MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N216951
Product Number: 002
Approval Date: Feb 1, 2023
Applicant Holder Full Name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD ENGLAND
Marketing Status: Discontinued
Patent and Exclusivity Information
JESDUVROQ (DAPRODUSTAT)
Proprietary Name: JESDUVROQ
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 2MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N216951
Product Number: 002
Approval Date: Feb 1, 2023
Applicant Holder Full Name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD ENGLAND
Marketing Status: Discontinued
Patent and Exclusivity Information
4MG
Marketing Status: Discontinued
Active Ingredient: DAPRODUSTAT
Proprietary Name: JESDUVROQ
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 4MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N216951
Product Number: 003
Approval Date: Feb 1, 2023
Applicant Holder Full Name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD ENGLAND
Marketing Status: Discontinued
Patent and Exclusivity Information
JESDUVROQ (DAPRODUSTAT)
Proprietary Name: JESDUVROQ
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 4MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N216951
Product Number: 003
Approval Date: Feb 1, 2023
Applicant Holder Full Name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD ENGLAND
Marketing Status: Discontinued
Patent and Exclusivity Information
6MG
Marketing Status: Discontinued
Active Ingredient: DAPRODUSTAT
Proprietary Name: JESDUVROQ
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 6MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N216951
Product Number: 004
Approval Date: Feb 1, 2023
Applicant Holder Full Name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD ENGLAND
Marketing Status: Discontinued
Patent and Exclusivity Information
JESDUVROQ (DAPRODUSTAT)
Proprietary Name: JESDUVROQ
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 6MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N216951
Product Number: 004
Approval Date: Feb 1, 2023
Applicant Holder Full Name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD ENGLAND
Marketing Status: Discontinued
Patent and Exclusivity Information
8MG
Marketing Status: Discontinued
Active Ingredient: DAPRODUSTAT
Proprietary Name: JESDUVROQ
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 8MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N216951
Product Number: 005
Approval Date: Feb 1, 2023
Applicant Holder Full Name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD ENGLAND
Marketing Status: Discontinued
Patent and Exclusivity Information
Proprietary Name: JESDUVROQ
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 8MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N216951
Product Number: 005
Approval Date: Feb 1, 2023
Applicant Holder Full Name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD ENGLAND
Marketing Status: Discontinued
Patent and Exclusivity Information